OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples.